Profile BioPartnering – San Francisco 2018

Magle Chemoswed is a specialty pharmaceutical and medical device company that develops and manufactures a broad range of pharmaceutical ingredients and medical devices. Magle Chemoswed boasts knowledge and experience across the whole value chain, in pharmaceuticals and medical devices, from idea to product, and with a strong sense of unity and belief in the future. Along with its strong and durable businesses, Magle Chemoswed is also focused on developing and introducing new products based on its unique patent protected bio-degradable polymer technology base. Currently, the Company has formulations with application in Advanced Wound Care, Surgical and Diagnostics and Drug Delivery. Our research and development have adapted our technologies to create gels, sponges, unwoven absorbable fibers, naturally degradable films and microporous polysaccharide microspheres which are used across our markets.

Magle Chemoswed's corporate headquarters are in Malmo, Sweden.

The technology base of the Company is derived from purified plant starch that is transformed through a process develop by the Company chemically creates microporous polysaccharide microspheres. Our microspheres have already been approved in one formulation by the FDA and have received CE mark. We anticipate final filings in the US and Europe of two more of our microspheres in 2018.

Microsphere size ranges from 10 µm to 2000 µm. Degradation time of our microspheres range from 10 minutes to 48 hours as microspheres and 10 minutes to 100 hours in formulated form. One of our microsphere families in size ranges 500 µm to 1200 µm can be pushed through a catheter without compromising the integrity of the microsphere. The technology has been used to incorporate substances up to the size of 6.6k Dalton and in earlier experiments peptides the size of peptides of 300k Dalton.

Currently, we have formulations with application in Advanced Wound Care, Surgical and Diagnostics and Drug Delivery. Our research and development have adapted our technologies to create gels, sponges, unwoven absorbable fibers, naturally degradable films and microporous polysaccharide microspheres which are used across our markets.

Based on our proprietary technology, we are finding innovative solutions to pressing medical needs. One formulation might act as a vessel for detecting enzymatic leakage in surgery, another can help treat infected serious wounds. We have a rich and exciting pipeline based on our technologies and unique formulations that will, we believe, provide valuable solutions to patients and healthcare providers in the future.

In addition to our in-house development and scale up Our chemists have extensive experience from process development for the pharma industry. This means we can help our customers with customized process optimization for their proprietary products, bringing their projects from lab scale through pilot and, if required, into full scale production. We perform multi-step synthesis and are experts in handling high potent compounds.

Our business model focuses on development and manufacturing of our own pharmaceutical and medical device products that are supplied to key and exclusive commercial partners for commercialization. Under this model, we go from idea to production. The Company intends to take the development of future product candidates to manufacture and supply to key distribution partners. By leveraging in- house manufacturing and up-scaling expertise the Company intends to offer innovative products in strategic areas to major pharmaceutical and biotechnology companies at a late stage following manufacturing scale up or regulatory approval.

Our partners range from major pharma to mid and small companies for supply, manufacturing and our process design research and development capabilities. On the medical design side we have strong on-going development collaboration with a market leader and a number of smaller research collaborations with leading surgical and wound care units in Europe and the United States.

In 2017, Magle AB – a medtech research and development company based in Skåne, in southern Sweden- merged with Chemoswed AB, an active pharmaceutical ingredients manufacturer with roots in Pharmacia and DuPont. Both companies brought with them extensive experience and longstanding operations – in Chemosweds case leading all the way back to 1944 – into the merger.

In 2006, we supported our market partner in obtaining worldwide approvals for one of our microsphere families.

In 2015, we received market authorization for an OTC product developed in-house that will come to the European market in 2018.

In 2016 we received European approval for our manufacturing process of Benserazide hydrochloride.

In 2017 we added a new patent family to our portfolio with our microspheres and have received grants across all major jurisdictions.

In 2018 we expect to receive FDA and CE approval for two of our innovative wound care products.

In 2018 we expect to receive grants on our second patent family incorporating our microspheres.